Impel Pharmaceuticals IMPL Stock
0.24 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
5.76M USD
LOW - HIGH [24H]
0.0000
-
0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Impel Pharmaceuticals Price Chart
Impel Pharmaceuticals IMPL Financial and Trading Overview
| Impel Pharmaceuticals stock price | 0.24 USD |
| Previous Close | 1.27 USD |
| Open | 1.3 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1300 |
| Day's Range | 1.25 - 1.31 USD |
| 52 Week Range | 0.93 - 10.75 USD |
| Volume | 11.78K USD |
| Avg. Volume | 54.06K USD |
| Market Cap | 30.87M USD |
| Beta (5Y Monthly) | -0.251056 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18 USD |
IMPL Valuation Measures
| Enterprise Value | 114.47M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.4606742 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.0225155 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 7.499 |
| Enterprise Value/EBITDA | -1.392 |
Trading Information
Impel Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.251056 |
| 52-Week Change | -85.22% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.75 USD |
| 52 Week Low | 0.93 USD |
| 50-Day Moving Average | 1.58 USD |
| 200-Day Moving Average | 3.07 USD |
IMPL Share Statistics
| Avg. Volume (3 month) | 54.06K USD |
| Avg. Daily Volume (10-Days) | 15.59K USD |
| Shares Outstanding | 23.75M |
| Float | 7.4M |
| Short Ratio | 5.07 |
| % Held by Insiders | 1.16% |
| % Held by Institutions | 75.46% |
| Shares Short | 465.62K |
| Short % of Float | 6.07% |
| Short % of Shares Outstanding | 1.95% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -546.44% |
| Gross Margin | 49.25% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -49.060% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 15.27M USD |
| Revenue Per Share (ttm) | 0.65 USD |
| Quarterly Revenue Growth (yoy) | 148.59% |
| Gross Profit (ttm) | 6.16M USD |
| EBITDA | -82251000 USD |
| Net Income Avi to Common (ttm) | -109409000 USD |
| Diluted EPS (ttm) | -4.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 35.47M USD |
| Total Cash Per Share (mrq) | 1.49 USD |
| Total Debt (mrq) | 119.78M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.329 |
| Book Value Per Share (mrq) | -3.07 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -93574000 USD |
| Levered Free Cash Flow (ttm) | -62585876 USD |
Profile of Impel Pharmaceuticals
| Country | United States |
| State | WA |
| City | Seattle |
| Address | 201 Elliott Avenue West |
| ZIP | 98119 |
| Phone | 206 568 1466 |
| Website | https://impelpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 160 |
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.
Q&A For Impel Pharmaceuticals Stock
What is a current IMPL stock price?
Impel Pharmaceuticals IMPL stock price today per share is 0.24 USD.
How to purchase Impel Pharmaceuticals stock?
You can buy IMPL shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Impel Pharmaceuticals?
The stock symbol or ticker of Impel Pharmaceuticals is IMPL.
Which industry does the Impel Pharmaceuticals company belong to?
The Impel Pharmaceuticals industry is Biotechnology.
How many shares does Impel Pharmaceuticals have in circulation?
The max supply of Impel Pharmaceuticals shares is 23.9M.
What is Impel Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Impel Pharmaceuticals PE Ratio is 0.00000000 now.
What was Impel Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Impel Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Impel Pharmaceuticals company belong to?
The Impel Pharmaceuticals sector is Healthcare.
Impel Pharmaceuticals IMPL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}